{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:11:37Z","timestamp":1775743897239,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.annder.2019.07.008","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T18:00:01Z","timestamp":1579716001000},"page":"221-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review"],"prefix":"10.1016","volume":"147","author":[{"given":"C.","family":"de Lorenzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vuilleumier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Abosaleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.07.008_bib0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2019.07.008_bib0110","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 Checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2019.07.008_bib0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/CMR.0000000000000500","article-title":"Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature","volume":"28","author":"Zhao","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annder.2019.07.008_bib0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2019.07.008_bib0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of antiprogrammed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.07.008_bib0130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-018-0048-5","article-title":"The new era of adjuvant therapies for melanoma","volume":"15","author":"Eggermont","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annder.2019.07.008_bib0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.annder.2019.07.008_bib0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clindermatol.2009.03.004","article-title":"Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies","volume":"28","author":"Fahri","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.annder.2019.07.008_bib0145","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMcp1103641","article-title":"Clinical practice. Lichen planus","volume":"366","author":"Le Cleach","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2019.07.008_bib0150","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2340\/00015555-2545","article-title":"Lichen planus in irradiated skin during nivolumab treatment","volume":"97","author":"Komori","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2019.07.008_bib0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/ced.13700","article-title":"Linear bullous lichen planus associated with nivolumab","volume":"44","author":"Biolo","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2019.07.008_bib0160","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CMR.0000000000000263","article-title":"PD1- inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases","volume":"26","author":"Wakade","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annder.2019.07.008_bib0165","first-page":"742","article-title":"Pembrolizumab-induzierter Lichen planus pemphigoides bei einem Patienten mit metastasiertem Melanom","volume":"15","author":"Schmidgen","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.annder.2019.07.008_bib0170","doi-asserted-by":"crossref","DOI":"10.5070\/D3241037930","article-title":"Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature","volume":"24","author":"Maarouf","year":"2018","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2019.07.008_bib0175","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/jdv.14203","article-title":"Multiple erosive lichen planus preceded by solitary lichen planus after combination therapy with nivolumab and radiation","volume":"31","author":"Komori","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.07.008_bib0180","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jdcr.2018.01.020","article-title":"Programmed cell death protein-1 inhibitor-induced granuloma annulare and hypertrophic lichen planus masquerading as squamous cell carcinoma","volume":"4","author":"Fontecilla","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2019.07.008_bib0185","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/ced.13315","article-title":"Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma","volume":"43","author":"Denny","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2019.07.008_bib0190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamaoncol.2016.4365","article-title":"New yellow plaques in a patient taking pembrolizumab","volume":"3","author":"Massey","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annder.2019.07.008_bib0195","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2019.07.008_bib0200","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx225","article-title":"ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819310853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819310853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:08:37Z","timestamp":1758971317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819310853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0151963819310853"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.07.008","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}